月経周期を考慮した正常子宮内膜のMR所見：子宮内膜病変との鑑別

The final, definitive version of this paper has been published in Acta radiologica by SAGE Publications Ltd, All rights reserved.Final publication is available at http://acr.sagepub.com/京都大学0048新制・課程博士博士(医学)甲第19582号医博第4089号新制||医||1014(附属図書館)32618京都大学大学院医学研究科医学専攻(主査)教授 山田 泰広, 教授 戸井 雅和, 教授 羽賀 博典学位規則第4条第1項該当Doctor of Medical ScienceKyoto UniversityDFA

Background, current role, and potential applications of radiogenomics.

UNLABELLED: With the genomic revolution in the early 1990s, medical research has been driven to study the basis of human disease on a genomic level and to devise precise cancer therapies tailored to the specific genetic makeup of a tumor. To match novel therapeutic concepts conceived in the era of precision medicine, diagnostic tests must be equally sufficient, multilayered, and complex to identify the relevant genetic alterations that render cancers susceptible to treatment. With significant advances in training and medical imaging techniques, image analysis and the development of high-throughput methods to extract and correlate multiple imaging parameters with genomic data, a new direction in medical research has emerged. This novel approach has been termed radiogenomics. Radiogenomics aims to correlate imaging characteristics (ie, the imaging phenotype) with gene expression patterns, gene mutations, and other genome-related characteristics and is designed to facilitate a deeper understanding of tumor biology and capture the intrinsic tumor heterogeneity. Ultimately, the goal of radiogenomics is to develop imaging biomarkers for outcome that incorporate both phenotypic and genotypic metrics. Due to the noninvasive nature of medical imaging and its ubiquitous use in clinical practice, the field of radiogenomics is rapidly evolving and initial results are encouraging. In this article, we briefly discuss the background and then summarize the current role and the potential of radiogenomics in brain, liver, prostate, gynecological, and breast tumors. LEVEL OF EVIDENCE: 5 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2017;47:604-620

Erratum to: Fertility-sparing for young patients with gynecologic cancer: How MRI can guide patient selection prior to conservative management

International audienceThe original version of this article unfortunately contained mistakes. The figures 7D, 7E and 7F were missing in the article and arrows were missing in the figures 6C, 8B and 11C. The year of publication and volume number for references 19, 79 and 87 have been updated. Also, the Table 2 layout has been improved for better readability. The Publisher apologizes for the mistakes and the inconvenience caused.Erratum for Fertility-sparing for young patients with gynecologic cancer: How MRI can guide patient selection prior to conservative management. [Abdom Radiol (NY). 2017